Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/22/2012US20120295839 Method of treatment and prophylaxis of bacterial vaginosis
11/22/2012US20120295835 Sgef controls macular, corpus callosum and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorogenic cell growth
11/22/2012US20120295834 Opioid Prodrugs with Heterocyclic Linkers
11/22/2012US20120295832 Novel Lipids and Compositions for Intracellular Delivery of Biologically Active Compounds
11/22/2012US20120294957 Treatment of lung cancer
11/22/2012US20120294956 Inhibition of dynamin related protein 1 to promote cell death
11/22/2012US20120294948 Vaccine
11/22/2012US20120294947 Oral Preparation Having Improved Quality
11/22/2012US20120294946 Modulator
11/22/2012US20120294945 Drug delivery system using hyaluronic acid-peptide conjugate micelle
11/22/2012US20120294944 Sustained-release nucleic acid matrix compositions
11/22/2012US20120294943 Extended-release formulation for reducing the frequency of urination and method of use thereof
11/22/2012US20120294942 Novel process for the preparation of roflumilast
11/22/2012US20120294941 Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
11/22/2012US20120294940 Rapidly disintegrating tablet in oral cavity
11/22/2012US20120294939 Direct compression formulation and process
11/22/2012US20120294938 Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production
11/22/2012US20120294937 New pharmaceutical dosage form for the treatment of gastric acid-related disorders
11/22/2012US20120294936 Reduced mass metformin formulations
11/22/2012US20120294935 Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
11/22/2012US20120294934 Transdermal compositions for anticholinergic agents
11/22/2012US20120294933 Use of PVP-Iodine Liposomes for Treatment of Acne
11/22/2012US20120294932 Prostate Carcinogenesis Predictor
11/22/2012US20120294931 Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof
11/22/2012US20120294930 Combination of kinase inhibitors and uses thereof
11/22/2012US20120294929 Method of diagnosing and treating cancer using b-catenin splice variants
11/22/2012US20120294928 Method of treating scars and b-catenin-mediated disorders using nefopam compounds
11/22/2012US20120294927 Wound dressing
11/22/2012US20120294926 Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
11/22/2012US20120294920 Wound dressing
11/22/2012US20120294915 Oral care compositions and methods
11/22/2012US20120294907 Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
11/22/2012US20120294905 Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR)
11/22/2012US20120294904 Polysialic acid-based n-trimethyl chitosan gel nanoparticles for systemic drug delivery
11/22/2012US20120294901 Novel cochleate formulations
11/22/2012US20120294900 Phosphorylated and Branched Dihydroxy-Pentane-Dione (DPD) Analogs as Quorum Sensing Inhibitors in Bacteria
11/22/2012US20120294897 Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer
11/22/2012US20120294882 Modified tuberculosis antigens
11/22/2012US20120294872 Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung
11/22/2012US20120294871 Modulation of gpcr-mediated camp production through lrp6 and its therapeutic application
11/22/2012US20120294869 Methods for Treating Fatty Liver Disease
11/22/2012US20120294856 Compounds inhibiting cd95 signaling for the treatment of pancreatic cancer
11/22/2012US20120294854 Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors
11/22/2012US20120294852 Antagonists of il-6 to raise albumin and/or lower crp
11/22/2012US20120294851 Cancer Therapies and Pharmaceutical Compositions Used Therein
11/22/2012US20120294846 Treatment of Pulmonary and Pleural Fibrosis Using HSP27 Inhibitors
11/22/2012US20120294840 Use Of Purified 2'-Fucosyllactose, 3-Fucosyllactose and Lactodifucotetraose as Prebiotics
11/22/2012US20120294838 Regulation of endogenous gene expression in cells using zinc finger proteins
11/22/2012US20120294831 Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
11/22/2012US20120294827 Polymer gel formulation
11/22/2012US20120294826 Methods, kits and compositions for ameliorating adverse effects associated with transfusion of aged red blood cells
11/22/2012US20120294823 Method for preparing silk sericin-PVA scaffold using genipin as crosslinking agent
11/22/2012US20120294822 Use of anti-cgrp antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated cgrp levels
11/22/2012US20120294817 Cosmetic compositions having long lasting shine
11/22/2012US20120294816 Cosmetic compositions having high shine
11/22/2012US20120294815 Cosmetic compositions having long lasting shine
11/22/2012US20120294812 Oral care compositions
11/22/2012US20120294805 DNA regulatory element for the expression of transgenes in neurons of a subject and uses thereof
11/22/2012US20120294804 Phenylethanolamine-based nmda receptor antagonists
11/22/2012US20120294801 Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
11/22/2012US20120292797 Solid pharmaceutical dispersions with enhanced bioavailability
11/22/2012US20120291875 Citrate-Based Dialysate Chemical Formulations
11/22/2012US20120291789 Medical composition for protuberance of epithelium
11/22/2012DE102011101952A1 Mit dendritischem Polyglycerolsulfat funktionalisierte Nanopartikel With dendritic polyglycerol sulfate functionalized nanoparticles
11/22/2012DE102011050519A1 Use of alkyl sulfur alkanoic acid derivatives for treating chronic inflammatory diseases e.g. multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, Wegener's granulomatosis and Churg-Strauss syndrome, Crohn's disease
11/22/2012CA2844765A1 Polymorph of rifaximin and process for the preparation thereof
11/22/2012CA2836676A1 Method for treating non-small cell lung cancer
11/22/2012CA2836655A1 Heparin-based compositions and methods for the inhibition of metastasis
11/22/2012CA2836579A1 Purine monophosphate prodrugs for treatment of viral infections
11/22/2012CA2836573A1 Improved peptide pharmaceuticals
11/22/2012CA2836568A1 Immunity induction agent
11/22/2012CA2836560A1 Macrocyclic therapeutic agents and methods of treatment
11/22/2012CA2836556A1 Immunity induction agent
11/22/2012CA2836474A1 Kinase modulation and indications therefor
11/22/2012CA2836463A1 Treating protein folding disorders with small molecule cftr correctors
11/22/2012CA2836449A1 Kinase inhibitors
11/22/2012CA2836417A1 Azaindole derivatives as tyrosine kinase inhibitors
11/22/2012CA2836410A1 Tyrosine kinase inhibitors
11/22/2012CA2836407A1 Method of treating postural reflex abnormality caused by parkinson's disease
11/22/2012CA2836405A1 Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
11/22/2012CA2836398A1 Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism
11/22/2012CA2836396A1 Method for egfr directed combination treatment of cancer
11/22/2012CA2836385A1 Method for treatment of advanced solid tumors
11/22/2012CA2836372A1 Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
11/22/2012CA2836353A1 Use of sigma ligands in diabetes type-2 associated pain
11/22/2012CA2836311A1 Amine derivatives as potassium channel blockers
11/22/2012CA2836277A1 Pharmaceutical compositions and methods for treating cancer
11/22/2012CA2836253A1 Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
11/22/2012CA2836215A1 Compound useful for preventing or treating irritable bowel syndrome and composition including same
11/22/2012CA2836203A1 Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
11/22/2012CA2836168A1 Method of treatment or prophylaxis of bacterial vaginosis
11/22/2012CA2836099A1 Compounds for use in treatment of mucositis
11/22/2012CA2836066A1 Treatment and management of cns disorders
11/22/2012CA2835940A1 Intranasal pharmaceutical dosage forms comprising naloxone
11/22/2012CA2835913A1 Use of cathepsin k inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure
11/22/2012CA2835911A1 Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
11/22/2012CA2835885A1 Medicaments and methods for treating cancer
11/22/2012CA2835845A1 Drug delivery system
11/22/2012CA2835835A1 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
11/22/2012CA2835819A1 Induction of immune tolerance using methotrexate
1 ... 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 ... 7860